ARB-002.T

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug NameARB-002.T

Drug Alias Nameanti-GPC3 CAR T-cell therapy (Arbele)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionGlypican-3 modulators

TargetsGlypican-3

Therapy Area/IndicationsOvarian NeoplasmsLiver NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryHong Kong

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesArbele Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesArbele Corp

Active IndicationsN/A

Inactive IndicationsOvarian NeoplasmsLiver NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A